ABSTRACT
Context 47,XXY/Klinefelter syndrome (XXY) is associated with impaired testicular function and differences in physical growth, metabolism, and neurodevelopment. Clinical features of XXY may be attributable to inadequate testosterone during the mini-puberty period of infancy.
Objective We tested the hypothesis that exogenous testosterone treatment positively effects short-term physical, hormonal, and neurodevelopmental outcomes in infants with XXY.
Design Double-blind randomized controlled trial, 2017-2021
Setting US tertiary care pediatric hospital
Patients Infants 30-90 days of age with prenatally identified, non-mosaic 47,XXY (n=71).
Intervention Testosterone cypionate 25mg intramuscular injections every 4 weeks for 3 doses
Main outcome measures The a priori primary outcomes were change in percent fat mass (%FM) z-scores and change in the total composite percentile on Alberta Infant Motor Scales (AIMS) assessment from baseline to 12 weeks.
Results The between group difference in change in %FM z-scores was -0.57 [95% CI -1.1, - 0.06], p=0.03), secondary to greater increases in lean mass in the testosterone-treated group (1.5±0.4 kg vs 1.2±0.4, p=0.001). Testosterone suppressed gonadotropins and inhibin B (p<0.001 for all). In contrast, there were no significant group differences in short term motor, cognitive, or language outcomes (p>0.15 for all).
Conclusions In this double-blind randomized controlled trial in infants with XXY, testosterone injections resulted in physical effects attributable to systemic androgen exposure; however, there was no impact on neurodevelopmental outcomes and the hypothalamic-pituitary-gonadal axis was suppressed. These results do not support routine testosterone treatment in infants with XXY, however long term follow up on physical health, neurodevelopment and testicular function is needed.
Competing Interest Statement
SD serves as a medical advisor for the non-profit Living with XXY and has received research funding from Association for X&Y Variations (AXYS), Living with XXY, Turner Syndrome Global Alliance, Pediatric Endocrine Society, Boettcher Foundation and the NIH. All other authors report no potential conflicts of interest.
Clinical Trial
NCT03325647
Funding Statement
This study was supported by NICHD K23HD092588, NIH/NCATS Colorado CTSA Grant Number UM1 TR004399 (REDCap) and departmental funds. Contents are the authors sole responsibility and do not necessarily represent official NIH views. The funders had no role in the design, data collection, data analysis, and reporting of this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study protocol was reviewed and approved by the Colorado Multiple Institutional Review Board, #17-1317. Written informed consent was obtained by a parent or legal guardian prior to any study procedures. The study was registered on clinicaltrials.gov (NCT03325647).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
Deidentified individual-level data are deposited in the NIH Data and Specimen Hub (DASH), a controlled-access data repository, and can be requested through the DASH Portal (dash.nichd.nih.gov).
